Body mass index is not a predictor of biochemical recurrence after radical prostatectomy in Dutch men diagnosed with prostate cancer
By
Dieuwertje E. G. Kok
Joep G. H. van Roermund
Katja K. Aben
Moniek W. M. van de Luijtgaarden
Herbert F. M. Karthaus
Oncko B. van Vierssen Trip
Ellen Kampman
J. Alfred Witjes
Lambertus A. L. M. Kiemeney
December 16, 2010
Clinical Scorecard: Body Mass Index Does Not Predict Biochemical Recurrence Following Radical Prostatectomy in Dutch Patients with Prostate Cancer
At a Glance
Category Detail
Condition Prostate cancer (PC) Key Mechanisms Assessment of body mass index (BMI) as a prognostic factor for biochemical recurrence (BCR) after radical prostatectomy (RP) Target Population Dutch men diagnosed with prostate cancer undergoing radical prostatectomy Care Setting Urology and oncology clinical settings in the Netherlands
Key Highlights
No significant association between BMI categories and adverse clinical or pathological prostate cancer characteristics at diagnosis. BMI was not a significant predictor of biochemical recurrence after radical prostatectomy in both univariable and multivariable analyses. Obese patients showed slightly higher tumor stage and prediagnostic PSA levels, but this did not translate into higher BCR risk. Guideline-Based Recommendations
Diagnosis
Use clinical and pathological staging (TNM classification) and Gleason score for prostate cancer assessment. Measure BMI but recognize it does not improve prediction of biochemical recurrence after radical prostatectomy. Management
Radical prostatectomy remains a primary treatment option; BMI should not influence treatment decisions regarding RP. Follow national prostate cancer guidelines for post-operative care and surveillance. Monitoring & Follow-up
Post-RP PSA monitoring at 6 weeks, then 3, 6, 9, 12 months, and every 6 months thereafter per national guidelines. Define biochemical recurrence as two consecutive PSA levels ≥0.2 ng/ml. Risks
Obesity does not independently increase risk of biochemical recurrence after radical prostatectomy. Consider other established pathological factors (Gleason score, surgical margins, lymph node status) for risk stratification. Patient & Prescribing Data
Dutch prostate cancer patients undergoing radical prostatectomy with known BMI data
BMI does not affect biochemical recurrence risk; treatment and follow-up protocols should not be altered based on BMI alone.
Clinical Best Practices
Collect accurate BMI data but interpret cautiously in prostate cancer prognosis. Rely on established clinical and pathological factors for predicting biochemical recurrence risk. Adhere to standardized PSA monitoring schedules post-radical prostatectomy. Exclude neoadjuvant androgen-deprivation therapy patients when evaluating BMI impact on outcomes. References
